Author:
Ayres A.S.,Bandeira G.A.,Ferraciolli S.F.,Takahashi J.T.,Moreno R.A.,de Souza Godoy L.F.,Casal Y.R.,de Lima L.G.C.A.,Frasseto F.P.,Lucato L.T.
Abstract
Neuronal and glioneuronal tumors usually have a benign course and may have typical imaging characteristics, allowing their diagnosis based on MR imaging findings. The most common lesions are dysembryoplastic neuroepithelial tumors and gangliogliomas, which have typical imaging characteristics. The fifth edition of theWorld Health Organization Classification of Tumors of the Central Nervous System, recently published in 2021, places greater emphasis on molecular markers to classify tumors of the CNS, leading to extensive changes in the classification of tumors, including neuronal and glioneuronal tumors. The 2021 revision included 3 new tumors types: multinodular and vacuolating neuronal tumor, diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (a provisional type), and myxoid glioneuronal tumor. Following these recent changes in the World Health Organization classification, we aimed to review the main imaging features of these lesions in relation to their histopathologic and molecular features.Learning Objectives: To list the neuronal and glioneuronal tumors; recognize the main imaging findings and histologic characteristics of neuronal and glioneuronal tumors; know the typical location of each neuronal and glioneuronal tumor; and become familiar with the main molecular alterations of neuronal and glioneuronal tumors to better understand their behavior
Publisher
American Society of Neuroradiology (ASNR)
Subject
Radiology, Nuclear Medicine and imaging
Reference56 articles.
1. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary;Louis;Acta Neuropathol,2016
2. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary;Louis;Neuro Oncol,2021
3. cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC);Louis;Acta Neuropathol,2018
4. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant;Louis;Acta Neuropathol,2018
5. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV;Brat;Acta Neuropathol,2018